U.S. Markets closed
  • S&P Futures

    3,654.00
    +30.75 (+0.85%)
     
  • Dow Futures

    29,869.00
    +240.00 (+0.81%)
     
  • Nasdaq Futures

    12,383.00
    +106.00 (+0.86%)
     
  • Russell 2000 Futures

    1,840.60
    +20.50 (+1.13%)
     
  • Crude Oil

    44.93
    -0.41 (-0.90%)
     
  • Gold

    1,786.30
    +5.40 (+0.30%)
     
  • Silver

    22.91
    +0.32 (+1.40%)
     
  • EUR/USD

    1.1962
    +0.0027 (+0.2273%)
     
  • 10-Yr Bond

    0.8440
    +0.0020 (+0.24%)
     
  • Vix

    20.57
    -0.27 (-1.30%)
     
  • GBP/USD

    1.3359
    +0.0027 (+0.2031%)
     
  • USD/JPY

    104.3710
    +0.0470 (+0.0451%)
     
  • BTC-USD

    19,574.62
    +64.73 (+0.33%)
     
  • CMC Crypto 200

    384.14
    +19.54 (+5.36%)
     
  • FTSE 100

    6,266.19
    -101.39 (-1.59%)
     
  • Nikkei 225

    26,824.46
    +390.84 (+1.48%)
     

BioMarin to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5 at 4:30pm ET

·1 min read

SAN RAFAEL, Calif., Oct. 22, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, November 5, at 4:30 p.m. ET to discuss third quarter 2020 financial results and provide a general business update.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)
BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

Dial-in Number
U.S. / Canada Dial-in Number: (866) 502-9859
International Dial-in Number: (574) 990-1362
Conference ID: 3291898

Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 3291898

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare genetic diseases. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.

Contacts:

Investors

Media

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-to-host-third-quarter-2020-financial-results-conference-call-and-webcast-on-thursday-november-5-at-430pm-et-301157647.html

SOURCE BioMarin Pharmaceutical Inc.